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Aims To compare the long-term safety and efﬁcacy of bioresorbable vascular scaffold (BVS) with everolimus-eluting stent
(EES) after percutaneous coronary interventions.
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Methods
and results
A systematic review and meta-analysis of randomized clinical trials comparing clinical outcomes of patients treated
with BVS and EES with at least 24 months follow-up was performed. Adjusted random-effect model by the Knapp–
Hartung method was used to compute odds ratios (OR) and 95% conﬁdence intervals (CI). The primary safety out-
come of interest was the risk of deﬁnite/probable device thrombosis (DT). The primary efﬁcacy outcome of interest
was the risk of target lesion failure (TLF). Five randomized clinical trials (n=1730) were included. Patients treated
with Absorb BVS had a higher risk of deﬁnite/probable DT compared with patients treated with EES (OR 2.93,
95%CI 1.37–6.26, P=0.01). Very late DT (VLDT) occurred in 13 patients [12/996 (1.4%, 95%CI: 0.08–2.5) Absorb
BVS vs. 1/701 (0.5%, 95%CI: 0.2–1.6) EES; OR 3.04; 95%CI 1.2–7.68, P=0.03], 92% of the VLDT in the BVS group
occurred in the absence of dual antiplatelet therapy (DAPT). Patients treated with Absorb BVS had a trend towards
higher risk of TLF (OR 1.48, 95%CI 0.90–2.42, P=0.09), driven by a higher risk of target vessel myocardial infarction
and ischaemia-driven target lesion revascularization. No difference was found in the risk of cardiac death.
...................................................................................................................................................................................................
Conclusion Compared with EES, the use of Absorb BVS was associated with a higher rate of DT and a trend towards higher
risk of TLF. VLDT occurred in 1.4% of the patients, the majority of these events occurred in the absence of DAPT.
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Introduction
Historically, the occurrence of stent thrombosis (ST) has jeopardized
the safety of percutaneous coronary interventions (PCIs). The pres-
ence of a metallic device in the coronary artery disrupts laminar flow
and creates a prothrombotic environment.1 The use of dual
antiplatelet therapy (DAPT), appropriate stent implantation tech-
niques (i.e. post-dilatation with adequate stent expansion), and the
advent of drug-eluting stents (DES) have significantly reduced the
rate of thrombotic complication following PCI.2–7 Furthermore, after
several iterations of DES, clinical outcomes have considerably im-
proved. In contemporary clinical trials, ST rates have been reported
* Corresponding author. Tel: þ31 10 206 2828, Email: patrick.w.j.c.serruys@pwserruys.com
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in <1% of cases even in all-comer population.8 The reduced strut
thickness and biocompatibility and stability of the polymers are likely
to be responsible for the improved performance of novel DES.
However, despite the low rates of events during the first year after
implantation, an unabated rate of target lesion failure (TLF) has been
observed at long-term follow-up after DES implantation, thus chal-
lenging the durability of the results after PCI.9
Focusing on long-term safety and efficacy, the concept of the bio-
resorbable scaffold was developed. Early scaffolding and very late re-
sorption was aimed at maintaining efficacy and returning the treated
region to the natural anatomical and physiological environment; this
would translate into a clinical benefit at long-term follow-up.10 The
bioresorbable vascular scaffold (BVS), i.e. Absorb BVS, have been
evaluated in six randomized clinical trials comprising 3708 pa-
tients.11–16 At 1-year follow-up, patients treated with Absorb BVS
have shown non-inferior rates of TLF compared with the fluoropoly-
mer everolimus-eluting stent (EES); however, a higher rate of target
vessel myocardial infarction (TVMI) and ST was observed.17,18 The
promise of the bioresorbable scaffold is to decrease very late (>1
year) device-related events. Therefore, long-term data from random-
ized clinical trials are awaited and has started to emerge. We sought
to compare the long-term safety and efficacy of BVS vs. EES by means
of a systematic review and meta-analysis.
Methods
Search strategy and selection criteria
Two independent reviewers (C.C. and T.A.) systematically searched
MEDLINE/Embase/CENTRAL applying the search terms ‘bioresorbable’,
‘scaffold’ ‘everolimus-eluting stent(s)’, and ‘randomized trial’. The search
was conducted in November 2016. No restrictions were applied con-
cerning language. Data were obtained from full articles in publication and
abstracts presented at the Transcatheter Cardiovascular Therapeutics
and EuroPCR meetings. The principal investigator for each of the studies
included was contacted and requested for additional analyses or follow-
up data. We included randomized clinical trials with patients who: (i)
underwent PCI for obstructive coronary artery disease; (ii) had at least
24 months clinical follow-up; and (iii) underwent PCI with implantation of
Absorb BVS. In the case of multiple publications with the same popula-
tion, the latest report was prioritized. Studies with inadequate data for ab-
straction, duplication of data, studies using other bioresorbable scaffolds
(polymeric or metallic) were not included. Data were extracted by the
same two investigators in agreement with PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) guidelines
Supplementary material online, Table S1.19 Bias assessment was per-
formed using the Cochrane Collaboration’s tool.20
Clinical outcomes
The primary safety outcome of interest was to compare the risk of defin-
ite/probable device thrombosis (DT) after BVS and EES implantation.
The primary efficacy outcome of interest was the risk of TLF [cardiac
death, TVMI, and ischaemia-driven target lesion revascularization (ID-
TLR)]. Patient/lesion characteristics and outcome data for TLF, cardiac
death, TVMI, and ID-TLR were collected. The longest available follow-up
was used for each study. Data on definite and probable DT were ex-
tracted from randomized trials according to the time of the event (i.e.
acute, <24h; subacute, 1–30 days; late, 30–365 days; very late, >365
days). Definitions of DT were according to the Academic Research
Consortium criteria. Definite DT was defined as angiographic confirm-
ation of DT or pathological confirmation of DT. Probable DTwas defined
any unexplained death within the first 30 days, irrespective of the time
after the index procedure, any MI that is related to documented acute
ischaemia in the territory of the implanted device without angiographic
confirmation of DT and in the absence of any other obvious cause.21
Statistical analysis
Categorical variables are reported as percentages, and continuous vari-
ables are reported as mean± SD or median (interquartile range) as ap-
propriate. Binary outcomes from individual studies were combined with
the random-effects model based on the DerSimonian and Laird method
adjusted by the Knapp–Hartung method to compute odds ratios (ORs)
with 95% confidence intervals (CIs) that were used for the comparison
between BVS and EES.22,23 The weighted rate of each event was calcu-
lated using the random-effects model. Weighted events are reported
with 95% intervals, with standard errors computed using Comprehensive
Meta-Analysis Software. I2 was calculated as a measure of statistical het-
erogeneity; I2 values of 25%, 50%, and 75% represented mild, moderate,
and severe inconsistency, respectively. Small study or publication bias
was explored with funnel plots. All analyses were performed using
Comprehensive Meta-Analysis (version 3.3, Englewood, NJ, USA) and
RevMan (Review Manager [RevMan] Version 5.3, The Cochrane
Collaboration, Copenhagen, Denmark).
Results
Five randomized clinical trials (n=1730 patients) comparing out-
comes of patients treated with BVS and EES were included
(Figure 1).24–28 Patients were randomized to receive PCI with Absorb
BVS (Abbott Vascular, Santa Clara, CA, USA; n=1015) or fluoro-
polymer–EES (Xience Stent, Abbott Vascular, Santa Clara, CA, USA;
n=635) or platinum–chromium–EES (Promus Element, Boston
Scientific, Natick, MA, USA; n=80). After PCI, P2Y12 inhibitors were
prescribed for a period ranging from >_6 to 12 months, while aspirin
was prescribed indefinitely. The median follow-up was 24 months
(range 24–36 months). Long-term follow-up data were assessed as
full-text articles in two studies and as abstract presentations in three.
Bias assessment is reported in the Supplementary material online,
Table S2. Baseline patient/lesion characteristics and long-term out-
comes are shown in Table 1. Patients included in this analysis had a
mean age of 61± 3 years, 77% were male, 62% had hypertension,
24% had diabetes mellitus, 33% were smokers, and acute coronary
syndrome was the clinical presentation in 48% of the patients.
Regarding lesion preparation, pre-dilatation, and post-dilatation were
performed in 89% and 54% of the cases, respectively. Long-term fol-
low-up was available in 95% (n=1642) of the population [94% (950/
1015) Absorb BVS vs. 97% (692/715) EES].
The primary safety outcome of interest of definite/probable DT had
occurred in 25 patients [22/996 (2.4%, 95% CI: 1.6–3.7) Absorb BVS
vs. 3/701 (0.9%, 95% CI: 0.3–2.1) EES]. Patients treated with Absorb
BVS had a higher risk of definite/probable DT compared with patients
treated with EES (OR 2.93, 95% CI: 1.37–6.26, P=0.01; I2= 0%; Figure
2A). Twelve thrombotic events occurred during the first year (i.e.
acute, subacute, and late DT), whereas very late device thrombosis
(VLDT) occurred in 13 patients [12/996 (1.4%, 95% CI: 0.08–2.5)
Absorb BVS vs. 1/701 (0.5%, 95% CI: 0.2–1.6) EES; OR 3.04, 95% CI:
1.20–7.68, P=0.03; Figure 2B]. Clinical, procedural, and outcomes of
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online, Table S3. From the 22 cases presenting with definite/probable
DT in the Absorb arm, the DAPT status was known in 19 cases; seven
(37%) of which were on DAPT at the time of the event, whereas nine
(47%) were on single antiplatelet therapy with acetyl salicylic acid and
three (16%) had interrupted the antiplatelet therapy. Noteworthy,
from the 12 patients presenting with VLDT in the Absorb BVS arm, 1
patient was on DAPT. Figure 3 shows the time course and frequency of
the definite/probable DT stratified by DAPT status.
The primary efficacy outcome of interest for TLF occurred in 122
patients [82/996 (9.3%, 95% CI: 7.5 to 11.4) Absorb BVS vs. 40/704
(6.6%, 95% CI: 4.8 to 8.8) EES]. Patients treated with Absorb BVS
showed a trend towards higher risk of TLF compared with patients
treated with EES (OR 1.48, 95% CI: 0.90–2.42, P=0.09, I2 = 0%; Figure
2C). In the Absorb BVS group, 55% (45/82) of the TLF events
occurred during the early period, whereas 45% (37/82) occurred at
late follow-up. This was in sharp contrast to the EES group, where
80% (32/40) occurred in the early period and 20% (8/40) occurred at
late follow-up. In patients treated with Absorb BVS, ID-TLR occurred
more frequently when compared with EES ID-TLR (OR 1.89, 95% CI:
1.15–3.13, P=0.02, I2 = 0%; Figure 2D). No difference was found in
the risk of TVMI and cardiac death between Absorb BVS and EES
(TVMI OR 2.25, 95% CI 0.81–6.19, P=0.09, I2 = 2.5% and cardiac
death OR 0.69, 95% CI 0.26–1.84, P=0.35, I2 = 0%; Figure 2E and F).
Discussion
The main findings of this systematic review and meta-analysis can be
summarized as follows: (i) a significantly higher risk of definite/
probable DT was observed in patients treated with Absorb BVS
compared with EES; (ii) very late scaffold thrombosis occurred in
1.4% of the patients treated with Absorb BVS, of which the majority
of these events occurred in the absence of DAPT; and (3) compared
with EES, Absorb BVS implantation was associated with a higher risk
of ID-TLR and a trend towards higher risk of TVMI and TLF.
Four randomized clinical trials with non-complex stable coronary
artery disease and two studies including patients with ST-elevation
myocardial infarction have been performed to evaluate the safety and
effectiveness of Absorb BVS.11–16 The ABSORB III trial, which is pow-
ered for clinical events had shown non-inferiority between BVS and
EES in the risk of TLF at 1-year follow-up.16 Several meta-analyses
performed at 1-year follow-up have suggested an increased risk of
TVMI and DT after Absorb BVS implantation.29,17 The present meta-
analysis extended the period of follow-up and confirmed a significant
increase in the risk of TVMI and DT. Moreover, despite an expected
long-term benefit with Absorb BVS, an opposite finding of an
increased late hazard was found, challenging the concept of long-
term benefit accredited to the bioresorbable scaffold. Also, the effi-
cacy of Absorb BVS was inferior to EES, reflected by a higher risk of
ID-TLR (OR 1.89, 95% CI 1.15–3.13, P=0.02).
Scaffold thrombosis appears to have a bimodal distribution over
time with one peak at the early period (<30 days) and another after
the first year. Following implantation, the thick non-embedded strut
may disrupt the laminar flow, create eddies with areas of reversal of
the flow behind the struts that have shown to predispose to fibrin de-
position and potentially DT.30,31 These rheological alterations might
be exacerbated by a relative high footprint of the scaffold seen in
cases with device/vessel mismatch and under deployment. Several
Figure 1 Flow chart for the trial selection process. RCTs, randomized controlled trials; BVS, bioresorbable vascular scaffold; EES, everolimus-
eluting stent.
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..registries have shown that image-guided scaffold implantation is associ-
ated with good outcomes.32,33 Furthermore, the use of optical coher-
ence tomography during scaffold thrombosis have identified
mechanical factors, such as underexpansion, undersizing, and geo-
graphical miss as predictors of early DT.32,33 Also, post-procedural
minimal lumen diameter has been described as the hallmark for DT;
therefore, an aggressive implantation strategy with high-pressure post-
dilatation with non-compliance balloon and imaging guidance has been
advocated to optimize scaffold expansion and reduce early events.34
The occurrence of VLDT was an unexpected finding.35 In a recent
meta-analysis of randomized and observational registries including
16 830 patients treated with BVS across the whole spectrum of cor-
onary artery disease, the computed weighted rate of VLDT was 1.0%
(95% CI 0.6–1.5%). Within the low-risk population included in
randomized trials, 12 cases of VLDT occurred. The incidence of
VLDT was 1.4% (95% CI 0.8–2.5%), which represents a three-fold in-
crease in the risk of VLDT compared with EES. The VLDT rate found
in the EES groups was 0.5%, which is consistent with previous re-
ports.36,37 Several authors have reported scaffold fragment protrud-
ing into the lumen (i.e. scaffold discontinuities or dismantling)
associated with VLDT.38 However, in the first-in-man study, in almost
half of the patients, discontinuities in the scaffold structure were
observed without any clinical repercussion.39 In the ABSORB II study,
six patients presented with VLDT, in one case optical coherence
tomography (OCT) assessment was performed at the time of the
event. No structural discontinuities or malaposition was found.25 In
the ABSORB Japan trial, OCT was performed in three cases at the
time of the VLDT, scaffold discontinuities, malapposition and/or un-
covered struts were observed in all cases.24 Also, the presence of
neoatheresclerosis, malaposition, late device recoil, and late resten-
osis have been reported as findings in cases presenting with
VLDT.33,40,41 The increased risk of VLDT observed with Absorb BVS
requires careful observation of the long-term outcomes in the on-
going studies and might anticipate the unblinding of the ABSORB III
trial.16
The absence of DAPT is the single most important predictor of
DT in the first year after PCI.42,43 In the population included in this
meta-analysis, 10 cases presented with definite/probable DT during
the first year, 6 of which were on DAPT, 2 interrupted the antiplate-
let therapy, and in 2 cases no data on DAPT were available. Although
in some cases, thrombosis may be related to DAPT cessation or ab-
sence, events also occurred while being on DAPT during the early
period pointing at other factors as the substrate for DT. It remains
unclear whether a prolonged course of DAPT would protect the pa-
tients treated with Absorb BVS from very late thrombotic events.
Notably, 92% of the VLDT occurred in the absence of DAPT. It can
Figure 2 Risk estimates of primary outcome of interest at long-term follow-up. Odds ratio (OR) for (A) definite/probable device thrombosis associated
with BVS vs. EES, (B) Target lesion failure, (C) target vessel myocardial infarction (D) target lesion failure, (E) ischaemia-driven target lesion revascularization,
and (F) cardiac death. The red diamonds indicate the point estimate and the left and the right ends of the lines the 95% confidence interval. BVS, bioresorb-
able vascular scaffold; EES, everolimus-eluting stent.
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therefore be hypothesized that a prolonged DAPT might benefit pa-
tients during the bioresorbtion period. Nonetheless, this question re-
quires further investigation and should be addressed in the ongoing
clinical trials.
The long-term advantage of avoiding a permanent implant in the
coronary artery is still the most reasonable approach to improve late
outcomes after PCI. The first generation of Absorb BVS has been
found to be associated with an increased risk of DT compared with
best-in-class DES. DT was shown to be the driving mechanism for the
increased risk of TVMI and ID-TLR assessed in a hierarchical manner in
randomized trials. In the next generation of bioresorbable scaffolds,
the resorption process should be faster, and in particular, the strut
thickness must be reduced. Also, the mechanical properties should be
enhanced by improving material tensile strength, stiffness, and ductabil-
ity, which could be achieved by controlling the composition, crystallin-
ity, and orientation of the polymer. The refinements in the technology
in combination with image-guided procedures, might ameliorate clinical
outcomes during the first year after implantation where half of the
thrombotic events occurred. Nonetheless, the occurrence of very late
events, and VLDT, in particular, warrant further investigation to delin-
eate the improvements required in future iterations.
Limitations
The main limitation of the meta-analysis is the lack of individual pa-
tient-level data. For that reason, further analysis to identify individual
factors associated with DT could not be investigated. The impact of
intravascular imaging-guided PCI could not be assessed in this cohort,
given the limited number of patients undergoing imaging-guided BVS
implantation and the lack of pre-specific intravascular ultrasound
(IVUS)/OCT protocol for PCI guidance. The absence of the DAPT
status in 3 of 22 patients with ST precluded a complete assessment of
the relationship between antiplatelet therapy and thrombotic events.
Also, the DAPT status of patients without clinical events was not
available. Even though we included all the studies available with long-
term follow-up, the sample size of 1730 patients is still underpow-
ered to detect differences in infrequent events such as DT. In add-
ition, due to the small number of randomized controlled trials
included in this meta-analysis, no publication bias assessment was
performed.
Conclusion
Compared with EES, the use of Absorb BVS was associated with a
higher rate of DT and a trend towards higher risk of TLF driven by a
higher risk of ID-TLR. Very late scaffold thrombosis occurred in 1.4%
of the patients, the majority of these events occurred in the absence
of DAPT.
Supplementary material
Supplementary material is available at European Heart Journal online.
Figure 3 Time course and frequency of scaffold thrombosis in randomized clinical trials. The red bars in the histogram represent the patients who
had interrupted DAPT, whereas blue bar represents patients on DAPT. The grey pattern represents the patients on acetyl salicylic acid as single-anti-
platelet therapy. A corresponding optical coherence tomography imaging finding shows themechanism underlying DT. In Panel A, a post-implantation
coronary optical frequency domain imaging image shows a representative example of under-deployment with a footprint of 38%. Panel B depicts a
VLDT case with scaffold discontinuity and fragments protruding to the lumen, malapposition, and uncovered struts. Panel C shows a case of VLDT
onDAPT with scaffold discontinuity, malapposition, and uncovered struts. Panel D shows another case of scaffold discontinuity with struts overhang-
ing to the lumen and uncovered struts. Panel E shows a VLDT at 967 days with eccentricity (eccentricity index 0.67) and uncovered struts. Three
cases of definite/probable DT were not plotted due to absence of data regarding the time of the event. DAPT, Dual antiplatelet therapy. DT, device
thrombosis; VLDT, very late device thrombosis. Reproduced with permission fromOnuma et al.24
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